Table 1.
Baseline characteristics of patients
| Variables | N = 35 |
|---|---|
| Age (years) | 53 (44–66) |
| Female, n (%) | 29 (81) |
| Body weight (kg) | 54.5 (47–66) |
| Disease duration (years) | 2.41 (0.75–7.5) |
| Methotrexate dose (mg/week) | 8 (8–10) |
| Concomitant glucocorticoid, n (%) | 7 (20) |
| DAS28-CRP | 4.17 (3.07–5.82) |
| DAS28-ESR | 5.14 (4.04–6.89) |
| SDAI | 22.8 (15.0–42.2) |
| CDAI | 19.2 (14.3–38.8) |
| Tender joint count (0–28) | 5 (1–13) |
| Swollen joint count (0–28) | 7 (4–12) |
| CRP (mg/dL) | 0.95 (0.08–2.68) |
| ESR (mm/h) | 46 (24–85) |
| Patients global VAS | 50 (27–66) |
| Physicians global VAS | 50 (18–75) |
| HAQ-DI score (unit) | 0.75 (0.38–1.50) |
| RF (IU/mL) | 62 (17–124) |
| ACPA (IU/mL) | 97.5 (11.7–166.5) |
| MMP-3 (ng/mL) | 172.7 (66.1–378.2) |
Values are median and interquartile range unless otherwise stated
ACPA anti-citrullinated peptide antibody, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score 28, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, SDAI Simplified Disease Activity Index, VAS visual analogue scale